Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;21(3):e14583.
doi: 10.1002/alz.14583.

Developing and validating a prediction tool for cerebral amyloid angiopathy neuropathological severity

Affiliations

Developing and validating a prediction tool for cerebral amyloid angiopathy neuropathological severity

Chenyin Chu et al. Alzheimers Dement. 2025 Mar.

Abstract

Introduction: Cerebral amyloid angiopathy (CAA) is a cerebrovascular condition, the severity of which can only be determined post mortem. Here, we developed machine learning models, the Florey CAA Score (FCAAS), to predict CAA severity (none/mild/moderate/severe).

Methods: Building on an auto-score-ordinal algorithm, the FCAAS models were developed and validated using data collected by three cohort studies of aging and dementia. The developed FCAAS models were digitized as a web-based tool. A pilot trial was conducted using this web-based tool.

Results: The FCAAS-4 achieved a mean area under the receiver operating characteristic curve (AUC-ROC) of 0.74 (95% confidence interval: 0.71-0.77) and a Harrell generalized c-index of 0.72 (0.70-0.75). Pilot trial results obtained a mean AUC-ROC of 0.82 (0.71-0.85) and Harrell generalized c-index 0.79 (0.73-0.82).

Discussion: The FCAAS models demonstrate a promising performance in predicting CAA severity. This framework holds the potential for predicting development of amyloid-related imaging abnormalities (ARIAs), given the CAA-ARIAs link.

Highlights: The severity of cerebral amyloid angiopathy (CAA) can only be determined post mortem. A web tool, the Florey CAA Score (FCAAS), was developed to predict CAA severity. The FCAAS holds the potential to be used for CAA risk stratification in clinics. CAA is linked to increased risk of amyloid-related imaging abnormalities (ARIAs). The framework used by FCAAS can possibly be adapted to predict ARIAs risk.

Keywords: AutoScore ordinal algorithm; amyloid‐related imaging abnormalities; cerebral amyloid angiopathy; machine learning; risk prediction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. Author disclosures are available in the supporting information.

Figures

FIGURE 1
FIGURE 1
Feature ranking. The x axis displays the importance determined by the random forest feature selection, and the y axis lists the names of all the features included in the study. A wider bar indicates greater importance. APOE, apolipoprotein E; MMSE, Mini‐Mental State Examination.
FIGURE 2
FIGURE 2
Parsimony plot for the FCAAS‐4. The plot displays the average mean AUC‐ROC values as an increasing number of features are used by the FCAAS‐4 model. The number annotated on each bar represents the cumulative number of features used. Taller bars indicate better performance. APOE, apolipoprotein E; AUC‐ROC, area under the receiver operating characteristic curve; FCAAS‐4, Florey Cerebral Amyloid Angiopathy Score, 4‐category model; MMSE, Mini‐Mental State Examination.
FIGURE 3
FIGURE 3
Score intervals and risk probabilities for the FCAAS‐4 model. The x axis represents the FCAAS score intervals, and the y axis indicates the probability of CAA severity (color‐coded). As the FCAAS score increases, the probability of more severe CAA also increases. CAA, cerebral amyloid angiopathy; FCAAS‐4, Florey Cerebral Amyloid Angiopathy Score, 4‐category model.

References

    1. Jäkel L, De Kort AM, Klijn CJ, Schreuder FH, Verbeek MM. Prevalence of cerebral amyloid angiopathy: a systematic review and meta‐analysis. Alzheimers Dement. 2022;18:10‐28. - PMC - PubMed
    1. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid‐related imaging abnormalities in amyloid‐modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367‐385. - PMC - PubMed
    1. Withington CG, Turner RS. Amyloid‐related imaging abnormalities with anti‐amyloid antibodies for the treatment of dementia due to Alzheimer's disease. Front Neurol. 2022;13:862369. - PMC - PubMed
    1. Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21:714‐725. - PMC - PubMed
    1. Kozberg MG, Perosa V, Gurol ME, van Veluw SJ. A practical approach to the management of cerebral amyloid angiopathy. Int J Stroke. 2021;16:356‐369. - PMC - PubMed

Publication types

LinkOut - more resources